FINWIRES · TerminalLIVE
FINWIRES

$BNTX

22 stories mentioning BNTX

Every FINWIRES story that references BNTX, newest first.

Asia Markets

European Equities Traded in US as ADRs Rise in Thursday Trading

European equities traded in the US as American depositary receipts rose late Thursday morning with the S&P Europe Select ADR Index climbing 1.7% to 1,874.97.From continental Europe, the gainers were led by biopharmaceutical company argenx (ARGX) and semiconductor company Sequans Communications (SQNS), which rose 2.7% and 2.6%, respectively. They were followed by biotech firm BioNTech (BNTX) and telecommunications company Nokia (NOK), which were up 2.5% and 1.6%, respectively.The decliners from continental Europe were led by software firm SAP (SAP) and internet ad firm Criteo (CRTO), which dropped 4.1% and 0.9%, respectively. They were followed by biotech firm Evaxion (EVAX) and consumer goods company Unilever (UL), which were off 0.4% and 0.1%, respectively.The gainers from the UK were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which climbed 8.8% and 4%, respectively. They were followed by lender HSBC (HSBC) and biotech firm Autolus Therapeutics (AUTL), which advanced 2.8% and 2.7%, respectively.The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and software company Endava (DAVA), which fell 4.6% and 1.1%, respectively. They were followed by biopharmaceutical companies Mereo BioPharma Group (MREO) and NuCana (NCNA), which lost 0.9% and 0.8%, respectively.

$ARGX$AUTL$BDRX$BNTX$CRTO$DAVA$EVAX$HSBC$MREO$NCNA$NOK$SAP$SLN$SQNS$TRIB$UL
Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index increasing 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.8%.The iShares Biotechnology ETF (IBB) advanced 1.7%.In corporate news, Medtronic (MDT) reported better-than-expected fiscal Q4 results on Wednesday, while the medical-device maker projected earnings and organic revenue growth for the current year. Its shares gained 5.8%.BioNTech (BNTX) cautioned that proposed healthcare reforms in Germany, due for a vote this summer, may put future investments in the country at risk, Bloomberg reported, citing Chief Commercial Officer Annemarie Hanekamp. BioNTech shares fell 0.8%.TG Therapeutics (TGTX) said its subcutaneous formulation of ublituximab showed "positive" results from a phase 1 trial comparing the multiple sclerosis therapy to the drug's intravenous version. Shares jumped past 10%.Maia Biotechnology (MAIA) shares rose 4.4% after the firm said Wednesday it has received clearance from the US Food and Drug Administration to open enrollment for the expansion of a phase 2 trial of ateganosine for advanced non-small cell lung cancer.

$BNTX$MAIA$MDT$TGTX
Sectors

Sector Update: Healthcare

Healthcare stocks rose Wednesday afternoon with the NYSE Healthcare Index increasing 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1%.The iShares Biotechnology ETF (IBB) advanced 1.7%.In corporate news, BioNTech (BNTX) cautioned that proposed healthcare reforms in Germany, due for a vote this summer, may put future investments in the country at risk, Bloomberg reported, citing Chief Commercial Officer Annemarie Hanekamp. BioNTech shares fell 1%.

$BNTX
Wire

Market Chatter: BioNTech Says Germany's Health Reforms Could Impact Investment Plans

BioNTech (BNTX) cautioned that proposed healthcare reforms in Germany, due for a vote this summer, could put future investments in the country at risk, Bloomberg reported Wednesday, citing Chief Commercial Officer Annemarie Hanekamp.Hanekamp said future investments in Germany will depend on whether policymakers can establish a stable and predictable framework for pharmaceutical companies, according to the report.The proposals, which aim to lower drug prices to curb healthcare costs, could also have implications for the US, the report added.BioNTech did not immediately respond to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $88.31, Change: $-0.83, Percent Change: -0.93%

$BNTX
Asia Markets

European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

European equities traded in the US as American depositary receipts started the trading week lower late Monday morning, declining 0.2% to 1,867.7 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by software firm SAP (SAP) and petroleum refiner Equinor (EQNR), which advanced 7.2% and 5.6% respectively. They were followed by accommodations booking site trivago (TRVG) and telecommunications company Nokia (NOK), which increased 5.2% and 4.8% respectively.The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and biotech firm Evaxion (EVAX), which dropped 7.2% and 4.8% respectively. They were followed by biotech firm BioNTech (BNTX) and lender Banco Bilbao Vizcaya Argentaria (BBVA), which fell 4.3% and 2.5% respectively.The gainers from the UK were led by software company Endava (DAVA) and oil and gas company BP (BP), which rose 5.9% and 3.6% respectively. They were followed by oil and gas company Shell (SHEL) and communications company WPP (WPP), which were up 2.2% and 0.9% respectively.The decliners from the UK and Ireland were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Mereo BioPharma Group (MREO), which lost 13.4% and 9.5% respectively. They were followed by biopharmaceutical company NuCana (NCNA) and pharmaceutical company Silence Therapeutics (SLN), which were down 7.7% and 4.4% respectively.

$AKTX$BBVA$BNTX$BP$DAVA$EQNR$EVAX$MREO$NCNA$NOK$SAP$SHEL$SLN$SQNS$TRVG$WPP
Asia Markets

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week

European equities traded in the US as American depositary receipts were rising late Friday morning, up 0.61% to 1,880.61 on the S&P Europe Select ADR Index, which is nearly flat for the week so far.From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and biotech firm BioNTech (BNTX), which rose 4.3% and 3% respectively. They were followed by software company SAP (SAP) and internet advertising firm Criteo (CRTO), which were up 2% and 0.4% respectively.The decliners from continental Europe were led by pharmaceutical company Ascendis Pharma (ASND) and telecommunications company Nokia (NOK), which fell 7.3% and 3% respectively. They were followed by accommodations booking site trivago (TRVG) and biopharmaceutical company Cellectis (CLLS), which were off 0.9% and 0.8% respectively.The gainers from the UK were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and communications company WPP (WPP), which advanced 2.4% and 1.1% respectively. They were followed by lenders Barclays (BCS) and HSBC (HSBC), which increased 1% and 0.9% respectively.The decliners from the UK and Ireland were led by biopharmaceutical companies Mereo BioPharma Group (MREO) and NuCana (NCNA), which dropped 6.6% and 4.4% respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and tobacco company British American Tobacco (BTI), which lost 3.5% and 1.8% respectively.

$ASND$BCS$BDRX$BNTX$BTI$CLLS$CRTO$EDAP$HSBC$MREO$NCNA$NOK$SAP$SLN$TRVG$WPP
Asia Markets

European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday

European equities traded in the US as American depositary receipts were trending slightly lower late Thursday morning, declining 0.1% to 1,873.2 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by internet advertising firm Criteo (CRTO) and medical device maker EDAP TMS (EDAP), which rose 3.3% and 3.2% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and software firm SAP (SAP), which were up 2.8% and 1.2% respectively.The decliners from continental Europe were led by telecommunications company Nokia (NOK) and brewing company Anheuser-Busch InBev (BUD), which fell 2.5% and 1.4% respectively. They were followed by biopharmaceutical company Grifols (GRFS) and biotech firm BioNTech (BNTX), which were down 1.1% and 0.3% respectively.The gainers from the UK were led by biopharmaceutical company Akari Therapeutics (AKTX) and biotech firm Autolus Therapeutics (AUTL), which advanced 43.9% and 1.5% respectively. They were followed by communications company WPP (WPP) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which increased 0.9% and 0.3% respectively.The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and insurance company Prudential (PUK), which dropped 4.2% and 2.3% respectively. They were followed by lender HSBC (HSBC) and biopharmaceutical company Amarin (AMRN), which lost 2% and 0.6% respectively.

$AKTX$AMRN$AUTL$BDRX$BNTX$BUD$CLLS$CRTO$EDAP$GRFS$HSBC$NOK$PUK$SAP$SLN$WPP
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Wednesday afternoon with the NYSE Healthcare Index gaining 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%.The iShares Biotechnology ETF (IBB) added 0.5%.In corporate news, BioNTech's (BNTX) cancer-drug pipeline is showing stronger early results and is approaching several important clinical milestones, improving confidence in the company's long-term outlook, UBS Securities said. BioNTech shares rose 1.4%.Corcept Therapeutics (CORT) shares jumped 9.7% after the company said it will resubmit its new drug application to the US Food and Drug Administration in the coming weeks for relacorilant to treat Cushing's syndrome.Boston Scientific (BSX) shares slumped 12% after CEO Mike Mahoney said this year has been "a bit more of a challenge" than anticipated.Guardant Health (GH) shares gained 5.6% after the company said its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines.

$BNTX$BSX$CORT$GH
Sectors

Sector Update: Healthcare

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index up 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.2%.The iShares Biotechnology ETF (IBB) added 0.6%.In corporate news, BioNTech's (BNTX) cancer-drug pipeline is showing stronger early results and is approaching several important clinical milestones, improving confidence in the company's long-term outlook, UBS Securities said in a report. UBS upgraded its rating on BioNTech stock to buy from neutral and raised its price target to $135 from $117. BioNTech shares rose 1.2%.

$BNTX
Wire

BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says

BioNTech's (BNTX) cancer-drug pipeline is showing stronger early results and is approaching several important clinical milestones, improving confidence in the company's long-term outlook, UBS Securities said Wednesday in a report.BioNTech is developing a new type of cancer medicine designed to both activate the immune system and cut off a tumor's blood supply, and early data from the company's lead program, pumitamig, in lung cancer have been encouraging in studies conducted in China and globally, with safety results that appear manageable, the report said.BioNTech's broader cancer pipeline remains under-recognized, and pumitamig may become competitive in several difficult-to-treat cancers, including triple-negative breast cancer and colorectal cancer, the report said. Global trial results look similar to early data from China, easing investor concerns that the treatment might not work the same way across regions, UBS said.A key moment for the field will come at the upcoming American Society of Clinical Oncology meeting, where Akeso and Summit Therapeutics (SMMT) will present overall survival data from their HARMONi-6 study, the report said. Strong results would help validate the drug approach BioNTech is pursuing and may shift sentiment around the company's oncology strategy, UBS said.UBS upgraded its rating on BioNTech stock to buy from neutral and raised its price target to $135 from $117.Price: $93.33, Change: $+1.08, Percent Change: +1.17%

$BNTX$SMMT
Asia Markets

European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading

European equities traded in the US as American depositary receipts were tracking lower late Wednesday morning, declining 0.48% to 1,880.02 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by internet advertising firm Criteo (CRTO) and biopharmaceutical company argenx (ARGX), which rose 5% and 2.8% respectively. They were followed by consumer goods company Unilever (UL) and biotech firm BioNTech (BNTX), which were up 2.1% and 1.9% respectively.The decliners from continental Europe were led by telecommunications companies Ericsson (ERIC) and Nokia (NOK), which dropped 4.1% and 3.4% respectively. They were followed by semiconductor company Sequans Communications (SQNS) and oil and gas company Eni (E), which lost 3.3% and 3% respectively.The gainers from the UK were led by biotech firm Autolus Therapeutics (AUTL) and software company Endava (DAVA), which advanced 3.7% and 3.4% respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and alcoholic beverage company Diageo (DEO), which increased 3% and 2.7% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Akari Therapeutics (AKTX) and oil and gas company BP (BP), which fell 13% and 3.2% respectively. They were followed by utilities company National Grid (NGG) and oil and gas company Shell (SHEL), which were down 2.2% and 2.1% respectively.

$AKTX$ARGX$AUTL$BNTX$BP$CRTO$DAVA$DEO$E$ERIC$NGG$NOK$SHEL$SLN$SQNS$UL
Research

UBS Upgrades BioNTech to Buy From Neutral, Adjusts Price Target to $135 From $117

BioNTech (BNTX) has an average rating of overweight and mean price target of $125.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$BNTX
Asia Markets

European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading

European equities traded in the US as American depositary receipts were heading higher late Monday morning, rising 0.88% to 1,825.10 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and healthcare tech company Royal Philips (PHG), which rose 4.6% and 2.9% respectively. They were followed by internet advertising firm Criteo (CRTO) and biopharmaceutical company Grifols (GRFS), which were up 2.8% each.The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and biotech firm BioNTech (BNTX), which dropped 3.2% and 2% respectively. They were followed by telecommunications company Nokia (NOK) and pharmaceutical company Ascendis Pharma (ASND), which were down 1.9% and 0.9% respectively.The gainers from the UK were led by biotech companies Autolus Therapeutics (AUTL) and Trinity Biotech (TRIB), which climbed 16% and 6.2% respectively. They were followed by communications company WPP (WPP) and educational publisher Pearson (PSO), which advanced 4.8% and 4.7% respectively.The decliners from the UK and Ireland were led by biopharmaceutical companies NuCana (NCNA) and Biodexa Pharmaceuticals (BDRX), which fell 8.3% and 3% respectively. They were followed by biopharmaceutical companies Amarin (AMRN) and Mereo BioPharma Group (MREO), which were off 2.1% and 1% respectively.

$AMRN$ASND$AUTL$BDRX$BNTX$CRTO$DBVT$EVAX$GRFS$MREO$NCNA$NOK$PHG$PSO$TRIB$WPP
Wire

BioNTech Approves $1 Billion ADS Repurchase Program

BioNTech (BNTX) has authorized a new $1 billion share repurchase program for its American depositary shares, the company said Thursday.The program will run until and including May 6, 2027, BioNTech said.Price: $94.10, Change: $-1.16, Percent Change: -1.22%

$BNTX
Sectors

Sector Update: Health Care Stocks Advance Tuesday Afternoon

Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3% each.The iShares Biotechnology ETF (IBB) was shedding 0.4%.In corporate news, Pfizer's (PFE) Q1 results surpassed analysts' estimates as robust demand across its key brands offset weakening sales of its COVID-19 products. Its shares declined 0.7%.Merck (MRK) shares added 0.4% after the company said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share. Terns' stock will no longer be listed on Nasdaq, it said.BioNTech (BNTX) shares dropped 3.5% after the company reported a wider adjusted loss and lower revenue in Q1.

$BNTX$MRK$PFE
Wire

Correction: BioNTech Q1 Adjusted Loss Widens, Revenue Declines; Reaffirms 2026 Revenue Outlook

(Corrects the year-ago revenue to 182.8 million euros in the third paragraph.)BioNTech (BNTX) reported a Q1 adjusted loss Tuesday of 1.95 euros ($2.28) per diluted share, widening from a loss of 1.79 euros a year earlier.Analysts polled by FactSet expected a loss of 1.27 euros.Revenue for the quarter ended March 31 was 118.1 million euros, compared with 182.8 million euros a year earlier.Analysts surveyed by FactSet expected 164.6 million euros.For 2026, the company reaffirmed revenue of between 2 billion euros and 2.30 billion euros. Analysts polled by FactSet expect 2.22 billion euros.BioNTech shares were down nearly 4.4% in Tuesday premarket activity.Price: $96.56, Change: $-2.79, Percent Change: -2.81%

$BNTX
Wire

Correction: Update: BioNTech Q1 Adjusted Loss Widens, Revenue Declines; Reaffirms 2026 Revenue Outlook

(Corrects the year-ago revenue to 182.8 million euros in the third paragraph.)BioNTech (BNTX) reported a Q1 adjusted loss Tuesday of 1.95 euros ($2.28) per diluted share, widening from a loss of 1.79 euros a year earlier.Analysts polled by FactSet expected a loss of 1.27 euros.Revenue for the quarter ended March 31 was 118.1 million euros, compared with 182.8 million euros a year earlier.Analysts surveyed by FactSet expected 164.6 million euros.For 2026, the company reaffirmed revenue of between 2 billion euros and 2.30 billion euros. Analysts expect 2.22 billion euros.The company said it plans to exit operations at manufacturing sites in Idar-Oberstein, Marburg and Singapore, as well as CureVac's sites, affecting up to about 1,860 positions. The moves are expected to be completed by 2027 and deliver about 500 million euros in annual cost savings by 2029.BioNTech shares were down 2.4% in Tuesday trading.Price: $96.80, Change: $-2.55, Percent Change: -2.57%

$BNTX
Asia Markets

European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading

European equities traded in the US as American depositary receipts were higher late Tuesday morning, rising 0.27% to 1,794.86 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by brewing firm Anheuser-Busch InBev (BUD) and medical device maker EDAP TMS (EDAP), which advanced 9% and 3% respectively. They were followed by telecommunications companies Ericsson (ERIC) and Nokia (NOK), which rose 2.5% and 2.4% respectively.The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and internet advertising firm Criteo (CRTO), which shed 9.7% and 3.9% respectively. They were followed by biotech firm BioNTech (BNTX) and consumer goods company Unilever (UL), which fell 3.1% and 0.6% respectively.The gainers from the UK were led by Biodexa Pharmaceuticals (BDRX) and insurance company Prudential (PUK), which climbed 32% and 2.2% respectively. They were followed by education company Pearson (PSO) and mining company BHP Group (BHP) were up 1.8% and 1.5% respectively.The decliners from the UK and Ireland were led by lender HSBC (HSBC) and Mereo BioPharma (MREO), which fell 5% and 2.1% respectively. They were followed by Lloyds Banking Group (LYG) and software firm Endava (DAVA), which were down 1.9% each.

$BDRX$BHP$BNTX$BUD$DAVA$EDAP$ERIC$HSBC$LYG$MREO$NOK$PSO$PUK$SQNS$UL
Wire

Update: BioNTech Q1 Adjusted Loss Widens, Revenue Declines; Reaffirms 2026 Revenue Outlook

(Updates with layoff plan in the sixth paragraph and recent stock price move in the last paragraph.)BioNTech (BNTX) reported a Q1 adjusted loss Tuesday of 1.95 euros ($2.28) per diluted share, widening from a loss of 1.79 euros a year earlier.Analysts polled by FactSet expected a loss of 1.27 euros.Revenue for the quarter ended March 31 was 118.1 million euros, compared with 182.8 billion euros a year earlier.Analysts surveyed by FactSet expected 164.6 million euros.For 2026, the company reaffirmed revenue of between 2 billion euros and 2.30 billion euros. Analysts expect 2.22 billion euros.The company said it plans to exit operations at manufacturing sites in Idar-Oberstein, Marburg and Singapore, as well as CureVac's sites, affecting up to about 1,860 positions. The moves are expected to be completed by 2027 and deliver about 500 million euros in annual cost savings by 2029.BioNTech shares were down 2.4% in Tuesday trading.Price: $96.96, Change: $-2.39, Percent Change: -2.41%

$BNTX
Asia Markets

European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week

European equities traded in the US as American depositary receipts were trending marginally higher late Friday morning, rising 0.05% to 1,824.45 on the S&P Europe Select ADR Index, which is up 1.25% for the week so far.From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and pharmaceutical company Novo Nordisk (NVO), which climbed 6.3% and 3.6% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and consumer goods company Unilever (UL), which advanced 3.3% and 3% respectively.The decliners from continental Europe were led by biotech firm BioNTech (BNTX) and furniture maker Natuzzi (NTZ), which dropped 6% and 3.5% respectively. They were followed by biopharmaceutical company DBV Technologies (DBVT) and petroleum refiner Equinor (EQNR), which lost 3.3% and 2.4% respectively.The gainers from the UK were led by educational publisher Pearson (PSO) and biopharmaceutical company Akari Therapeutics (AKTX), which rose 3.2% and 2.8% respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and cruise line operator Carnival (CUK), which were up 2.7% and 2.5% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Amarin (AMRN) and oil and gas company BP (BP), which fell 2.8% and 1.9% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and oil and gas company Shell (SHEL), which were down 1.4% and 1.2% respectively.

$AKTX$AMRN$BCYC$BDRX$BNTX$BP$CLLS$CUK$DBVT$EQNR$NOK$NTZ$NVO$PSO$SHEL$UL

Showing 1-20 of 22